Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;278(7):2637-2640.
doi: 10.1007/s00405-020-06408-7. Epub 2020 Oct 6.

ACE2 expression in allergic airway disease may decrease the risk and severity of COVID-19

Sunita Chhapola Shukla  1
Affiliations

ACE2 expression in allergic airway disease may decrease the risk and severity of COVID-19

Sunita Chhapola Shukla. Eur Arch Otorhinolaryngol. 2021 Jul.

Abstract

The coronavirus disease (COVID-19) is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and presents with respiratory symptoms which can be life threatening in severe cases. At the start of the pandemic, allergy, asthma, and chronic obstructive pulmonary disease (COPD) were considered as risk factors for COVID-19 as they tend to exacerbate during respiratory viral infections. Recent literature has not shown that airway allergic diseases is a high-risk factor or that it increases the severity of COVID-19. This is due to a decrease in Angiotensin-converting enzyme 2 (ACE2) gene expression in the nose and bronchial cells of allergic airway diseases. Conventional asthma treatment includes inhaled corticosteroids (ICS), allergen immunotherapy (AIT), and biologics, and should be continued as they might reduce the risks of asthmatics for coronavirus infection by enhancing antiviral defence and alleviating inflammation.

Keywords: Allergen immunotherapy (AIT); Allergic rhinitis; Angiotensin-converting enzyme 2 (ACE2); Asthma; COVID-19; Inhaled corticosteroids (ICS); SARS-CoV-2; Transmembrane protease serine 2 (TMPRSS2).

PubMed Disclaimer

References

    1. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi: 10.1016/j.ijid.2020.03.017. - DOI - PMC - PubMed
    1. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280 e278. doi: 10.1016/j.cell.2020.02.052. - DOI - PMC - PubMed
    1. Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect. 2020;9(1):601–604. doi: 10.1080/22221751.2020.1739565. - DOI - PMC - PubMed
    1. Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon- stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181:1016–1035. doi: 10.1016/j.cell.2020.04.035. - DOI - PMC - PubMed
    1. Radzikowska U, Ding M, et al. Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Basic Transl Allergy Immunol. 2020 doi: 10.1111/ALL.14429. - DOI - PMC - PubMed

Substances